NEOS S&P 500 High Income ETF (SPYI) Stock Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Volume
- Income / Options OverlaySector
- $54.4252W High
- $47.9852W Low
- -Typical Hold Time
- -Enterprise Value
- -Div Yield
- -Trading Activity
Track NEOS S&P 500 High Income ETF (SPYI) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, NEOS S&P 500 High Income ETF has traded between a low of $47.98 and a high of $54.42, highlighting its annual price range. Buy and sell NEOS S&P 500 High Income ETF shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Most Recent News
Gossamer Bio achieves exceptional financial efficiency with ROIC 106 times its capital cost.
Gossamer Bio stands out in the biotech sector by generating a Return on Invested Capital (ROIC) of 697.21%, vastly exceeding its Weighted Average Cost of Capital (WACC) of 6.57%. This results in an ROIC to WACC ratio of 106.17, meaning the company cr...
ACCO Brands shows strong growth potential with a 41.5% price target and solid financial health.
ACCO Brands Corporation, known for products like Five Star and Swingline, is showing promising growth despite a recent 3% dip in its stock price over 10 days. The stock has gained about 5.2% over the past month, suggesting positive momentum. Analysts...
Argenx stock jumps 16.66% after positive Phase III trial for autoimmune drug Vyvgart.
Argenx's stock surged 16.66% following positive Phase III ALKIVIA trial results for its autoimmune drug Vyvgart Hytrulo, showing significant efficacy in treating autoimmune myositis. Analyst firm William Blair reaffirmed an 'Outperform' rating, refle...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.